Accuracy and differential bias in copy number measurement of CCL3L1 in association studies with three auto-immune disorders by Carpenter, Danielle et al.
RESEARCH ARTICLE Open Access
Accuracy and differential bias in copy number
measurement of CCL3L1 in association studies
with three auto-immune disorders
Danielle Carpenter
1, Susan Walker
1, Natalie Prescott
2, Joost Schalkwijk
3 and John AL Armour
1*
Abstract
Background: Copy number variation (CNV) contributes to the variation observed between individuals and can
influence human disease progression, but the accurate measurement of individual copy numbers is technically
challenging. In the work presented here we describe a modification to a previously described paralogue ratio test
(PRT) method for genotyping the CCL3L1/CCL4L1 copy variable region, which we use to ascertain CCL3L1/CCL4L1
copy number in 1581 European samples. As the products of CCL3L1 and CCL4L1 potentially play a role in
autoimmunity we performed case control association studies with Crohn’s disease, rheumatoid arthritis and
psoriasis clinical cohorts.
Results: We evaluate the PRT methodology used, paying particular attention to accuracy and precision, and
highlight the problems of differential bias in copy number measurements. Our PRT methods for measuring copy
number were of sufficient precision to detect very slight but systematic differential bias between results from case
and control DNA samples in one study. We find no evidence for an association between CCL3L1 copy number and
Crohn’s disease, rheumatoid arthritis or psoriasis.
Conclusions: Differential bias of this small magnitude, but applied systematically across large numbers of samples,
would create a serious risk of false positive associations in copy number, if measured using methods of lower
precision, or methods relying on single uncorroborated measurements. In this study the small differential bias
detected by PRT in one sample set was resolved by a simple pre-treatment by restriction enzyme digestion.
Background
Within the last few years there have been significant
developments in our understanding of copy number var-
iation (CNV) and its contribution to human genetic var-
iation. It is now apparent that CNVs are both a frequent
form of variation throughout the human genome, and
are implicated in disease susceptibility [1,2].
In general, three forms of CNVs can be defined; inser-
tion, deletion and multi-allelic, but accurate and stan-
dardised measurement of individual copy numbers is
technically challenging. In particular the measurement
of multi-allelic CNVs is the most problematic, more
specifically those with higher copy numbers, where it is
essential that the technical challenges of copy number
genotyping are robust for all copy number classes and
do not result in the systematic rejection of samples with
high copy number. Repeated exclusion of particular gen-
otypes will lead to mis-representation of copy number
variation at a particular locus in a given population due
to an artificially reduced apparent mean copy number.
To define the full variation at a particular copy number
variable locus it is critical that these technical challenges
are overcome successfully.
Furthermore, and perhaps most importantly, accurate
CNV measurement is essential in the context of case
control association studies. Critically, inaccurate copy
number measurements can lead to differential bias
between cases and controls and result in false positive
findings [3]. In SNP based studies differential bias can
lead to differences in allele frequency estimates between
batches of samples. In the context of CNVs bias can be
seen as a systematic shift in the raw measurement
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differential mis-classification of samples by either over-
or under-estimation of the integer copy number. Differ-
ences in DNA source and quality can cause small
changes in the measured copy number distribution of
case and control samples [2]. Furthermore, the power to
detect disease associations in case control studies is also
reduced with inaccurate genotyping of copy number [4].
Thus accurate determination of copy number is limited
by the precision of the methodology used, which needs
to be robust and replicable to give maximum power and
reduce spurious disease associations.
New whole-genome genotyping platforms now incor-
porate probes to interrogate multiple CNVs [5], and
have begun to yield associations between such variants
and disease phenotypes [2]. However, even these meth-
ods are sensitive to DNA quality [6] and are limited in
their accuracy to genotype multiallelic loci. The recent
report by the Wellcome Trust Case Control Consor-
tium [2] discusses in detail the potential artefactual
influences on copy number determination and demon-
strates the potential for reporting spurious associations
with CNVs, especially multiallelic regions. To comple-
ment whole genome approaches, particularly for com-
plex diseases where effect sizes are likely to be small,
locus specific methods are also required for investigat-
ing multiallelic CNV loci. Such targeted methods can
provide sufficiently accurate data to limit the potential
for false positive or negative results as a result of dif-
ferential bias. Locus specific methods are generally
PCR-based, and perhaps the most widely used is Real-
Time quantitative PCR, which depends upon the quan-
tification of a copy variable test locus in comparison
with an unrelated reference locus [7]. However, differ-
ential amplification efficiencies between test and refer-
ence loci can generate inaccuracies, particularly for
high copy number measurements where the relative
difference in ratio between test and reference products
is smaller for neighbouring copy number classes. An
alternative locus specific method with improved relia-
bility for CNV determination is the paralogue ratio test
( P R T )[ 8 ] .T h i sm e t h o du s e sas i n g l ep a i r so fp r i m e r s
to amplify specifically two products simultaneously,
one from a copy-constant reference locus and the
other from the copy variable test locus of interest. The
copy number of the test locus is then estimated from
the ratio of test to reference products. Recently, the
accuracy of the PRT method has been directly com-
pared with a Real-Time quantitative PCR method of
copy number measurement for b-defensins and shown
to be the more accurate and robust approach [9]. The
PRT method has previously been used to successfully
analyse both b-defensins and CCL3L1/CCL4L1 copy
numbers [10,11].
T h ec o p yv a r i a b l eg e n e sCCL3L1 and CCL4L1 located
on chromosome 17q12 lie in a 90 kb repeat unit, neigh-
bouring the paralogous, but copy invariant, genes CCL3
and CCL4 [12]. CCL3L1 and CCL4L1 show 96%
sequence similarity at both the nucleotide and protein
level with their respective paralogues [13,14]. All four
genes (CCL3, CCL3L1, CCL4 and CCL4L1)e n c o d ec h e -
mokines, chemotactic cytokines, which play an impor-
tant role in the immune response by attracting
lymphocytes and macrophages to sites of infection and
inflammation. Furthermore they are all natural ligands
f o rC C R 5 ,t h ec o - r e c e p t o ru s e db yH I V - 1f o rc e l le n t r y
[15,16], with CCL3L1 being the most potent [17]. As
such there have been a number of association studies
focused on CCL3L1 copy number variation and HIV-1
susceptibility [7,18,19]. However, the reported associa-
tions are under dispute and the accuracy of CCL3L1
measurement is a major factor in the debate [20-23].
Here we report a modification of a previously
described PRT method to measure CCL3L1/CCL4L1
copy number making it more efficient, cost effective and
convenient. As CCL3L1 and CCL4L1 function as an
attractant of inflammatory mediators we have performed
three case control studies with autoimmune phenotypes
(Crohn’s disease, rheumatoid arthritis and psoriasis). We
subsequently discuss in detail the accuracy of the PRT
methodology used, the precision in CCL3L1/CCL4L1
copy number measurement and highlight the implica-
tions of differential bias with copy number variation.
Results
CCL3L1 copy number measurement
The paralogue ratio test was used to genotype the copy
number of the CCL3L1/CCL4L1 copy variable region in
a total of 1661 samples of European origin. The copy
number measures generated with the “CCL3A” and
“CCL3C” measurement systems were shown to be
equivalent in accuracy (see additional file 1, Figure S1).
In the majority of cases (1550/1661) the three indepen-
dent PRT assays assigned concordant measurements of
copy number for samples (to within 0.5 of the integer
value for 85% of samples and to within 0.75 for 93% of
samples) (see table 1). Samples showing a higher level of
discordance between the integer copy numbers assigned
by the PRT systems were assayed for two microsatellites
that are present within the repeat unit [11]. The micro-
satellite genotyping allowed confident integer copy num-
ber calling for 31 of the discordant samples, leaving 2
s a m p l e sf o rw h i c ht h ec o p yn u m b e rc a n n o tb ec o n f i -
dently resolved, and these have therefore been excluded
from further analysis.
All 61 internal duplicate samples showed complete con-
cordance of integer copy number, and an average cali-
brated copy number was generated from all PRT
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Page 2 of 9systems. For a total of 78 samples the PRT assays failed
to produce sufficient signal, presumably due to low
DNA concentration of these particular samples. The dis-
tribution of the unrounded copy numbers for 1581 sam-
ples is shown in Figure 1.
The different PRT systems (CCL3A/C, CCL4A and
LTR61A) show a high level of agreement in all the Eur-
opean samples. This supports the previous observation
by our lab [11] and suggests that discordancy between
copy numbers of CCL3L1 and CCL4L1 as previously
reported is rare [24]. Furthermore the agreement
between all PRT systems indicates that variation in the
copy number of the reference genes CCL3 and CCL4 is
also uncommon in Europeans.
Accuracy and error of PRT measurements
Germline copy numbers are integers, and thus we
assume that precision and accuracy of measurement will
be shown by a discrete distribution reflecting the under-
lying integer values [4]. The distributions of the raw
data shown in Figure 1 clearly demonstrate PRT values
clustering around the inferred integers. The overall stan-
dard deviation (normalised for copy number) of the full
dataset was 0.075; and for each cohort separately the
standard deviations were 0.069 for the European con-
trols, 0.066 for Crohn’s disease samples, 0.077 for rheu-
matoid arthritis samples and 0.081 for Dutch psoriasis
and control samples. These values are both small and
consistent between datasets, indicating that the variance
inherent in the CCL3L1/CCL4L1 PRT measurement sys-
tem is low, and the precision of the PRT measurements
in estimating integer copy number is high and reprodu-
cible between datasets.
The mean and standard deviation, normalised stan-
dard deviations and predicted probability of error for
the full dataset are shown in table 2. The data show
Table 1 Breakdown of total numbers and concordance of PRT systems for the European samples by disease cohort
Disease cohort No Concordance
(within 0.5)
Concordance
(within 0.75)
Discordance Missing data
Random UK controls 252 243 96% 252 100% 0 0
Crohn’s disease 657 565 85% 607 92% 9 1.4% 41
Rheumatoid arthritis 274 189 69% 240 88% 12 4.4% 22
Psoriasis 478 408 85% 451 94% 12 2.5% 15
TOTAL 1661 1405 85% 1550 93% 33 1.9% 78
Figure 1 Distribution of the unrounded copy number values for 1581 European samples. The distribution shows a common range of 0-4
copies, with few high copy number outliers. The distribution shows peaks centred on the integer values with gaps between most clusters.
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within 0.1 of the corresponding integer and that the
standard deviations for each copy class specifically are
sufficiently low that the probability of integer error is
also small, further highlighting the reliability of the PRT
system to accurately and reproducibly measure CCL3L1/
CCL4L1 copy number. Though the estimates of the
probability of error of copy number calling are small,
there is an increase for higher copy numbers which is
likely the result of smaller sample size and potentially
the greater variance observed at the higher copy
numbers.
Differential bias
Differential bias in genotyping can lead to false positive
or false negative associations in case control analyses
and therefore it is essential that this is addressed in
datasets. In particular, CNV measurements may be sus-
ceptible to shifts in results arising from physicochemical
properties of DNA samples, properties which may be
systematically different between cases and controls. We
reasoned that if such shifts were present in our own
data, they should be evident as different distributions of
raw measurements around integer values. Examination
of such distributions showed no significant difference
between the three PRT systems (CCL3C, CCL4A and
LTR61A) using the European control samples. A cumu-
lative frequency plot of the unrounded copy number
data for the predicted 2-copy samples is shown in
Figure 2. This suggests that the raw data measurements
from the three independent PRT systems perform
equivalently and generate comparable measures of the
copy number. Thus it is appropriate to compare the
three systems and this will not lead to differential error
in the scoring of the copy numbers.
Distributions around integer values were also com-
pared between case and control samples for each clinical
cohort. Owing to the precision of the PRT copy number
measurement small, but systematic, differences in copy
number measurement between cases and controls can be
detected. Cumulative frequency plots were generated of
the unrounded copy number distributions around the 2-
copy integer for the clinical cohorts, shown in Figures 3a,
b and 3c. The figures show a clear similarity between the
case and control data for the Crohn’s disease and rheu-
matoid arthritis cohorts. This suggests that there is no
differential bias in these datasets and that the copy num-
ber genotyping is equivalent in the cases and controls.
However, the cumulative frequency plot for the psoriasis
cohort identifies a small but significantly different distri-
bution of copy number measurement (p < 0.0001, t-test)
between cases (mean = 1.91) and controls (mean = 2.03)
(see Figure 3c). This difference between cases and
Table 2 Mean, deviations and predicted probability of error for the unrounded copy number values for 1581
European samples
Copy Number No Mean Standard deviation Normalised Standard deviation Specific deviation Probability of error
0 30 -0.033 0.068
1 300 1.033 0.097 0.096 0.102 7.2 × 10
-07
2 877 2.021 0.142 0.071 0.101 4.9 × 10
-04
3 313 3.012 0.178 0.059 0.103 4.9 × 10
-03
4 49 4.071 0.203 0.051 0.108 1.9 × 10
-02
5 9 4.977 0.346 0.069 0.155 0.149
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Figure 2 A cumulative frequency plot of unrounded copy
number values measured by the three PRT systems, (CCL3C,
CCL4A and LTR61A) among samples assigned a copy number
of 2 for the random UK control samples (149 samples). All three
systems show a similar distribution around the mean value,
displaying no obvious heterogeneity between the systems.
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Page 4 of 9controls was also observed for the 1-copy samples (p <
0.001) and 3-copy samples (p < 0.01) (data not shown).
Basis of differential bias
Interestingly, two different DNA extraction methods
were used for the psoriasis cases and controls. All the
cases were extracted using a Qiagen kit, whereas the
controls were extracted using a salting-out procedure. It
has previously been suggested that different methods of
DNA extraction between cases and controls can lead to
differential bias due to differences in DNA quality and
purity [6]. We envisaged that one potential physico-
chemical difference between genomic DNA preparations
could be the level of residual protein, and in particular
locally bound proteins that might be unusually tenacious
in particular regions. We therefore tested whether separ-
ating our PRT amplicon from neighbouring DNA by
restriction digestion might remedy the differential bias.
Digestion with the restriction enzyme BccIl e a v e sa l l
PRT amplification sites used here intact, but separates
them from neighbouring sequences that may potentially
influence PCR efficiencies differentially. The discrepancy
between cases and controls was rectified by pre-diges-
tion of DNA samples with BccI: after digestion with
BccI the cumulative frequency plot showed no signifi-
cant difference between cases and control samples (data
not shown), (two sets of control experiments were also
performed; one set of samples was incubated at 37°C
but lacked BccI and the other set of samples was incu-
b a t e da t3 7 ° Cw i t he n z y m eb u f f e rp r e s e n tb u tn o tBccI.
Differential bias was still observed with all these control
samples). The differential bias did not alter the integer
copy number calling of the samples. Although it may
not be the cause of all or even most cases of differential
bias, the observation that restriction digestion appears
to mitigate differences between the case and control
DNA collections does suggest that residual local protein
binding might underlie the bias initially observed in this
study.
Association studies
Association analyses were performed for the different
clinical cohorts. A two-tailed t-test was carried out to
test for significant differences in the means between the
Crohn’s disease cases (n = 616), and European controls
(n = 252); between the rheumatoid arthritis cases (n =
252), and European controls (n = 252); and between the
psoriasis cases (n = 195), and the Dutch controls (n =
Figure 3 A cumulative frequency plot for controls (solid black
line) and cases (broken black line) for Crohn’s disease samples
(a), rheumatoid arthritis (b), and psoriasis (c) with copy
number of 2. There is no significant difference between the means
of the distributions for the Crohn’s disease and rheumatoid arthritis
samples, whereas for the psoriasis samples the values for cases are
significantly shifted towards lower values relative to the controls.
Pre-digestion with the enzyme BccI, prior to PRT (d) shown here on
a subset of 20 Dutch samples, resolves the significant difference
between case and control samples.
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tests. The frequency of cases and controls with each
copy number are shown in tables 3, 4, and 5 for Crohn’s
disease, rheumatoid arthritis and psoriasis respectively.
The frequency distributions of cases and controls are
shown in additional file 2 figure S2. These represent
relatively small-scale association tests, and are only well
powered to detect relatively large effects; for example,
simulations show that the Crohn’s disease cohort (616
cases and 252 controls) has about 90% power to detect
an effect with an odds ratio of 1.5 at a significance level
of 5%, and about 70% to demonstrate an effect at signifi-
cance level 1%. By contrast, the same cohort would only
have about 50% power to demonstrate an effect with
significance level of 5% with an odds ratio of 1.3.
Discussion
Over the last few years there has been a surge in inter-
est in copy number variation in relation to human varia-
tion and disease and accurate copy number
measurements are thus essential. Here we describe a
more efficient modification of an already published
method of locus specific copy number measurement for
CCL3L1/CCL4L1 to ascertain copy number for a total of
1581 independent European samples.
We present here three association studies of CCL3L1/
CCL4L1 measured with PRT, and find no association
for variation in copy number with the autoimmune phe-
notypes Crohn’s disease, rheumatoid arthritis or psoria-
sis. It is interesting to note however, that, for the
Crohn’s disease cohort, whilst the sample size is small,
there are 7 cases with an integer copy number of 5 and
greater, and yet there were no controls observed to have
copy numbers greater than 4 (table 3). It has previously
been reported that higher copy numbers of CCL3L1/
CCL4L1 are associated with increased protein levels and
enhanced chemotactic activity [24] which could suggest
that higher copy numbers lead to increased recruitment
of immune mediators and potential pathology. The role
of both CCL3L1 and CCL4L1 predicts an influence of
copy number on autoimmune disorders, but this was
not supported by our data.
There is a previous report of an association between
rheumatoid arthritis and CCL3L1/CCL4L1 copy number
in a New Zealand cohort [25]. It is possible that the
association study presented here for rheumatoid arthritis
lacks power, but this association was also not supported
by the recent report from the Wellcome Trust Case-
Control Consortium (WTCCC) on CNV associations in
eight common diseases [2].
Detailed analysis of the raw data generated from the
PRT methodology shows the copy number genotyping
to have a high degree of accuracy in integer copy num-
ber prediction, and that the level of accuracy is reprodu-
cible between European datasets. Inaccurate genotyping
can lead to differential bias, a proportional shift in raw
measurements that differ between sample batches,
which we were able to investigate here due to the accu-
racy of the copy number measurement assay. Whilst evi-
dence for differential bias was detected here with one of
the case control cohort, this was resolved. This observa-
tion, however, does highlight the importance of examin-
ing raw data thoroughly prior to association analysis.
Fortunately, the analysis presented here was with lower
copy numbers and so the small differential bias observed
did not alter the integer copy number calling. However it
Table 3 Distribution of integer copy numbers in Crohn’s
disease cases and controls
Copy number Cases Controls
0 14 (2.27%) 4 (1.59%)
1 119 (19.34%) 49 (19.44%)
2 331 (53.73%) 149 (59.13%)
3 124 (20.13%) 45 (17.86%)
4 21 (3.41%) 5 (1.98%)
5 4 (0.65%)
6 1 (0.16%)
7 1 (0.16%)
80
9 1 (0.16%)
TOTAL 616 252
Table 4 Distribution of integer copy numbers in
rheumatoid arthritis cases and controls
Copy number Cases Controls
0 2 (0.79%) 4 (1.59%)
1 51 (20.24%) 49 (19.44%)
2 139 (55.16%) 149 (59.13%)
3 49 (19.44%) 45 (17.86%)
4 10 (3.97%) 5 (1.98%)
5 1 (0.39%)
TOTAL 252 252
Table 5 Distribution of integer copy numbers in psoriasis
cases and controls
Copy number Cases Controls
0 6 (3.08%) 4 (1.51%)
1 25 (12.82%) 56 (21.13%)
2 115 (58.97%) 143 (53.96%)
3 45 (23.08%) 49 (18.49%)
4 2 (1.03%) 11 (4.15%)
5 2 (1.03%) 2 (0.75%)
TOTAL 195 265
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cise measurement assay, differential bias could have easily
caused frequent misclassification of integer copy number,
potentially leading to false positive associations [3].
Conclusion
In conclusion, the data presented here failed to find any
association between disease and CCL3L1 copy number
on three auto-immune disorders (Crohn’s disease, rheu-
matoid arthritis and psoriasis) but did identify an exam-
ple of differential bias. This was resolved by simple pre-
treatment by restriction enzyme digestion; emphasising
the importance of preparing case and control DNA
together and encouraging the presentation of raw data
to allow assessment of accuracy or bias in published
association studies.
Methods
Samples
Control DNA samples
192 random control samples from the UK were used for
direct comparison between the “CCL3A” and “CCL3C”
PRT systems. These samples were from the European
Collection of Cell Cultures (ECACC) Human Random
Control (HRC) panels 1 and 2 (http://www.hpacultures.
org.uk).
These ECACC samples were also used for the Crohn’s
disease and rheumatoid arthritis association studies,
along with the parents (n = 60) from the International
HapMap phase I CEPH samples (http://ccr.coriell.org),
making a total of 252 random European control sam-
ples. All DNA provided was extracted from lymphoblas-
toid cell lines.
Samples from patients with Crohn’s disease, rheumatoid
arthritis and psoriasis
All samples were collected after informed consent and
with appropriate ethical approval; details can be found
in [9,10,26]. There were 657 Crohn’s disease patient
samples of UK origin, collected from patients attending
clinics in London or Newcastle [9]. DNA was obtained
from 274 rheumatoid arthritis patient samples of UK
origin, although due to limited DNA volumes only 252
samples were successfully genotyped. The psoriasis sam-
ples and matched controls were from a cohort of sam-
ples from Nijmegen, Holland and have already been
described [10]. In brief, there were 276 control samples
from the Nijmegen Biomedical Study (NBS), and 202
unrelated psoriatic cases. All patients were diagnosed
with psoriasis vulgaris, and classified as having moderate
to severe psoriasis.
I no r d e rt oa d d r e s sw h e t h e rt h e r ei sa n yp o p u l a t i o n
stratification of CCL3L1 copy number across Europe a
t-test was performed between the Dutch control samples
(n = 202) and the UK ECACC control samples (n =
192). There was no significant difference between the
means of the two control datasets suggesting that that
there is no population stratification across Europe and
that the control samples are appropriate for the associa-
tion studies.
Copy number measurement
The paralogue ratio test (PRT)
CCL3L1 copy number of the psoriasis samples and the
random control samples was measured using a minor
modification of the PRT method previously described
[11]. In the modified method the system “CCL3A” was
changed to a similar system, termed “CCL3C”,w h e r e
the primer pairs for amplification of both CCL3/
CCL3L1 were re-designed. The primers were specifically
designed using DNA sequence flanking exon 1 of CCL3
and CCL3L1, and therefore will not amplify from the
CCL3L1 pseudogene, which lacks exon 1. For the
“CCL3C” PRT 1 μM each of primers FAM-labelled
CCL3CF (GGC TAA GAC CCC TTC TAG AG) with
CCL3CR (AAT CAT GCA GGT CTC CAC T) were
used which gives products of 252 bp for CCL3 and 258
bp for CCL3L1.T h e“CCL3C” system PCR is more effi-
cient than the “CCL3A” system and could be multi-
plexed with both the “CCL4A” and “LTR61A” systems
i nas i n g l eP C Rr e a c t i o nw i t har e a c t i o nm i x t u r eo f0 . 5
U Taq DNA polymerase (NEB) in a buffer with final
concentrations of 50 mM Tris-HCl pH8.8, 12.5 mM
ammonium sulphate, 1.4 mM magnesium chloride, 7.5
mM 2-mercaptoethanol, 125 μg/ml BSA and 200 μM
each dNTP. PCR cycle conditions were 24 cycles of 95°
C for 30s, 55°C for 30s, 70°C for 60s followed by a final
hold at 70°C for 40 minutes. CCL3L1 copy number of
Crohn’s disease and rheumatoid arthritis samples were
measured from genomic DNA using the paralogue ratio
test (PRT) method previously described [11].
In order to reduce variation due to batch effects or
plate position artefacts, case and control samples were
interspersed within 96-well plates and genotyping was
performed blind to the clinical status of each sample.
Furthermore, all plates included some duplicate samples
that were measured independently on separate plates to
ensure consistency. For all PRTs fragment analysis of
the test and reference loci was carried out by electro-
phoresis on an ABI3100 36 cm capillary using POP-4
polymer with an injection time of 30 s at 1 kV. Products
from the PRT reactions were mixed with 10 μl HiDi for-
mamide with ROX-500 marker (Applied Biosystems).
Two microsatellite PCRs were also performed, as
described previously [11], for any sample showing
inconsistencies between the PRT systems.
Copy number measurement of the PRT products
The peak areas were extracted using GeneMapper software
(Applied Biosystems) and the ratio of test locus to reference
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and standardise unknown DNA samples, DNA samples of
established copy number were included in each PCR in tri-
plicate (ECACC samples, C0075 with a copy number (CN)
= 1; C0150 with CN = 2; C0007 with CN = 3; and C0877
with CN = 4). A linear regression was applied to the cluster
of ratios generated from the standard reference DNA sam-
ples and used to calibrate the inference of copy number
from the ratios of the unknown samples. Copy number
values from each of the independent PRT systems were
compared and an arithmetic mean value was calculated
from all PRT measurements to generate a single
unrounded copy number value for each sample.
Statistical analysis
Association studies
In order to test the difference in means between the
copy number distributions of cases and control sam-
ples a two-tailed t-test was performed. Analyses were
performed between European control samples and
Crohn’s disease or rheumatoid arthritis samples (both
UK), and between Nijmegen psoriasis cases and Dutch
controls.
Accuracy and error measurements
The accuracy of the PRT measurements to ascertain
correctly the copy number for each sample was assessed
in each dataset from the unrounded copy number data.
All analyses were performed in Excel (Microsoft 2007)
and SPSS (Version 16). For each dataset the mean and
standard deviation of the unrounded data were mea-
sured for each copy number group. To obtain a general
standard deviation of the whole dataset, and for each
copy number class, the data were normalised by dividing
the unrounded copy number value by the predicted
integer copy number.
To estimate the probability of error inherent in a PRT
system it is assumed that measurements of copy number
values are normally distributed around each integer.
From the observed data the mean and standard devia-
tion for each copy number can be estimated and used
to calculate the probability of mis-assigning a sample to
the appropriate integer class.
To support the probability of misclassification approx-
imation, a Kolmogorov-Smirnov test for normality was
performed with the random control samples for copy
number classes 1, 2 and 3. All 3 groups showed no sig-
nificant deviation from normality (see additional file 3
figure S3 for Q-Q plots).
Differential bias
Differential bias was first examined for each PRT system
(CCL3C, CCL4A and LTR61A) using the random con-
trol samples, to ensure that the different PRT systems
are not differentially sensitive to DNA quality nor are
there differences in PCR efficiencies that could lead to
bias. Together this ensures that all the PRT data can be
collated into a single value. Differential bias was also
investigated between cases and control samples in the
clinical cohorts, by comparing a normalised cumulative
frequency plot of the unrounded copy numbers around
a ni n t e g e rc o p yn u m b e ro f2 ,a st h i si st h em o s tf r e -
quent copy number group, and therefore with greatest
power to show any discrepancies. Where a difference
was observed, a two-tailed t-test was performed to
examine the significance of the deviation and other inte-
ger classes were investigated.
Additional material
Additional file 1: Figure S1. The distribution of unrounded copy
number values for 192 ECACC samples typed with the “CCL3C” system,
with discernable peaks around the integers, comparable to the original
“CCL3A” distribution (figure 2a in Walker et al. 2009 [11]). The “CCL3A”
method had an overall standard deviation of 0.087, whereas the
modified “CCL3C” method had a standard deviation of 0.058 for the full
dataset.
Additional file 2: Figure S2. Histograms of the cases and control
samples for Crohn’s disease samples (a), rheumatoid arthritis (b), and
psoriasis (c), with cases in black and controls in white. The histograms
show no significant difference between the cases and controls for all
datasets.
Additional file 3: Figure S3. Q-Q plots of the control samples fitted to a
normal distribution for copy numbers of 1 (n = 49) (control1) (a), 2 (n =
149) (control2) (b) and 3 (n = 45) (control3) (c).
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